Hengrui Pharmaceuticals' share price rose to become the first pharmaceutical company to break 300 billion A-shares

On June 12th Hengrui Pharmaceuticals closed up 0.82 per cent at 78.66 yuan, 289.661 billion yuan. Hengrui Pharmaceuticals hit a high of 83.29 yuan on June 7, with a market capitalization of 306.507 billion yuan, and was the first A-share pharmaceutical company to exceed 300 billion yuan in market value.
2017 net profit attributable to shareholders of listed companies was RMB3,217 million, according to hengrui Pharmaceuticals' annual report.
2017, Hengrui Pharmaceuticals revenue of 13.836 billion yuan, net profit of 3.217 billion yuan, in the 18 years of listing, respectively, increased about 28 times, 48 times, while the share price increased by more than 250 times, far higher than the performance growth.
On June 12, Guizhou Maotai closed at 799.19 yuan, with a market value of 103.941 billion yuan.
the white wine leader Guizhou Maotai and the pharmaceutical leader Hengrui medicine which is more risky? First of all, from the price-to-earnings ratio, to yesterday's share price and last year's net profit ratio, Guizhou Maotai price-earnings ratio of 37.07 times, Hengrui Pharmaceuticals price-earnings ratio of 90.04 times. The price-to-earnings ratios of the two companies are not in the same grade.
, Hengrui Pharmaceuticals' performance growth rate is far from that of Guizhou Maotai. Hengrui Pharmaceutical's net profit attributable to shareholders of listed companies increased by 24.25 percent year-on-year last year, 16.95 percent year-on-year in the first quarter, and net profit after deducting non-profit increased by only 12.28 percent. The net profit attributable to shareholders of listed companies in Guizhou Maotai increased by 61.97 percent year-on-year last year and 38.93 percent year-on-year in the first quarter.'s net profit increased 24.25% last year 16.95% yoY in the first quarter of 2018
Hengrui Pharmaceutical's 2017 annual report shows that the company's 2017 operating income was 138.8%. 3.6 billion yuan, up 24.72% YoY; net profit attributable to shareholders of listed companies was RMB3,217 million, up 24.25% YoY; and net cash flow from operating activities was RMB2,547 million, down 1.75% YoY.
Hengrui Pharmaceuticals' first-quarter 2018 report showed that the company's operating income in the first quarter of 2018 was RMB3,857 million, up 21.70 percent over the same period;
According to media reports, Hengrui Pharmaceuticals dynamic price-earnings ratio of 90.47 times, dynamic price-to-earnings ratio of 18.51 times, while the healthcare industry's median dynamic price-earnings ratio is only 40.71 times, the average price-to-earnings ratio of 6.58 times. Hengrui Pharmaceutical's price-earnings ratio is more than 2 times the industry average, and the price-to-earnings ratio is close to 3 times the industry average.'s net profit rose 61.97 percent last year38.93 percent year-on-year in the first quarter of 2018
1.8 billion yuan, up 49.81% YoY; net profit attributable to shareholders of listed companies was RMB27,079 million, up 61.97% YoY; and net cash flow from operating activities was RMB22,153 million, down 40.85 percent YoY.
First Quarter 2018, the company's operating income was RMB17,466 million, up 31.24% YoY, while the net profit attributable to shareholders of listed companies was RMB8,507 million, up 38.93% over the same period, and net cash flow from operating activities was RMB4,936 million, down 19.21% yoY. (China Economic Network)